Jazz Pharmaceuticals (JAZZ) News Today → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free JAZZ Stock Alerts $105.25 -0.21 (-0.20%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 8:05 AM | prnewswire.comJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024June 1 at 7:32 AM | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded to "Strong-Buy" at StockNews.comMay 31 at 10:12 PM | marketbeat.comStockNews.com Upgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Strong-BuyStockNews.com upgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday.May 30 at 7:30 AM | prnewswire.comJazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024May 30 at 5:40 AM | marketbeat.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Lifted by UBS Group AGUBS Group AG boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 18.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 172,947 shares of the specialty pharmaceutMay 29 at 4:15 PM | prnewswire.comJazz Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 29 at 7:45 AM | prnewswire.comZanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract CancerMay 28, 2024 | finance.yahoo.comNodThera Announces Appointment of Daniel Swisher as Chief Executive OfficerMay 26, 2024 | marketbeat.comCommerce Bank Purchases Shares of 55,138 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Commerce Bank acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 55,138 shares of the specialty pharmaceutical cMay 24, 2024 | marketbeat.comFranklin Resources Inc. Decreases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Franklin Resources Inc. trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 15.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 877,509 shares of the specialty pharmaceuticalMay 23, 2024 | investorplace.com7 Blue-Chip Stocks to Buy Now: May 2024May 23, 2024 | marketbeat.comDimensional Fund Advisors LP Cuts Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Dimensional Fund Advisors LP trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 765,846 shares of the specialtMay 23, 2024 | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 22, 2024 | marketbeat.comTrexquant Investment LP Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Trexquant Investment LP bought a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 56,607 shares of the specialty pharmaceutical company's stock, valued aMay 22, 2024 | prnewswire.comJazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee VolunteerismMay 21, 2024 | marketbeat.comGW&K Investment Management LLC Sells 19,980 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)GW&K Investment Management LLC reduced its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 5.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 366,865 shares of theMay 19, 2024 | marketbeat.comRobeco Institutional Asset Management B.V. Has $21.87 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Robeco Institutional Asset Management B.V. trimmed its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 37.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 177,818 shares of the sMay 17, 2024 | investorplace.com3 Cheap Blue-Chip Stocks to Buy Now: May 2024May 16, 2024 | uk.finance.yahoo.comGlobal Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5%May 16, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Sells 8,324 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Charles Schwab Investment Management Inc. trimmed its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 505,654 shares oMay 15, 2024 | marketbeat.comNatixis Advisors L.P. Cuts Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Natixis Advisors L.P. lowered its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 45.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,425 shares of the specialty pharMay 12, 2024 | marketbeat.comJump Financial LLC Invests $3.66 Million in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Jump Financial LLC bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 29,782 shares of the specialty pharmaceutical company's stock, valued at approximately $3,663,000. Several otherMay 11, 2024 | marketbeat.comThompson Siegel & Walmsley LLC Grows Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Thompson Siegel & Walmsley LLC grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 30.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 352,562 shares of the specialty pharmaceutical compMay 10, 2024 | msn.comAvadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drugMay 9, 2024 | investorplace.com7 Cannabis Stocks to Buy for a Smoking-Hot 2024May 9, 2024 | marketbeat.comSwiss National Bank Trims Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Swiss National Bank lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 9.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 187,600 shares of the specialty pharmaceutMay 8, 2024 | benzinga.comNeena M Patil Implements A Sell Strategy: Offloads $548K In Jazz Pharmaceuticals StockMay 8, 2024 | insidertrades.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Sells $548,250.00 in StockMay 7, 2024 | marketbeat.comInsider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) EVP Sells 5,000 Shares of StockJazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) EVP Neena M. Patil sold 5,000 shares of the business's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.May 7, 2024 | finance.yahoo.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comInternational Assets Investment Management LLC Acquires New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)International Assets Investment Management LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 58,548 shares of theMay 5, 2024 | marketbeat.comLSV Asset Management Has $288.22 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)LSV Asset Management reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,343,227 shares of the specialty pharmaceutical company's stock after selling 28,950 sharesMay 3, 2024 | marketbeat.comLos Angeles Capital Management LLC Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Los Angeles Capital Management LLC cut its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 309,379 shares of the specialty pharmaceutical companyMay 3, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)HC Wainwright reaffirmed a "buy" rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday.May 3, 2024 | marketbeat.comBarclays Trims Jazz Pharmaceuticals (NASDAQ:JAZZ) Target Price to $200.00Barclays lowered their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an "overweight" rating on the stock in a research note on Friday.May 3, 2024 | finance.yahoo.comJazz Pharmaceuticals First Quarter 2024 Earnings: Misses ExpectationsMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jazz Pharmaceuticals’ Resilient Base and Promising Pipeline Drive Positive OutlookMay 2, 2024 | marketbeat.comJazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 52-Week Low at $103.01Jazz Pharmaceuticals (NASDAQ:JAZZ) Sets New 12-Month Low at $103.01May 2, 2024 | markets.businessinsider.comOptimistic Outlook for Jazz Pharmaceuticals Despite Q1 ChallengesMay 2, 2024 | markets.businessinsider.comDemystifying Jazz Pharmaceuticals: Insights From 15 Analyst ReviewsMay 2, 2024 | marketbeat.comJazz Pharmaceuticals (NASDAQ:JAZZ) Given Buy Rating at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $222.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday.May 1, 2024 | investorplace.comJAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 1, 2024 | marketbeat.comJazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2024 Earnings GuidanceJazz Pharmaceuticals (NASDAQ:JAZZ) updated its FY 2024 earnings guidance. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus estimate of 18.930. The company also issued revenue guidance of $4.0 billionillion-$4.2 billionillion, compared to the consensus estimate of $4.1 billionillion.May 1, 2024 | sfgate.comJazz: Q1 Earnings SnapshotMay 1, 2024 | seekingalpha.comJazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call PresentationMay 1, 2024 | prnewswire.comJazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care ConferenceMay 1, 2024 | prnewswire.comJazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial GuidanceMay 1, 2024 | marketbeat.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Cut by Russell Investments Group Ltd.Russell Investments Group Ltd. lowered its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 84.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 243,105 shares of the specialty pharmaceutical cApril 30, 2024 | finance.yahoo.comJazz Pharmaceuticals Focuses on Taking Actions To Positively Impact the Planet This Earth MonthApril 27, 2024 | marketbeat.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by California Public Employees Retirement SystemCalifornia Public Employees Retirement System raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 42.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 278,294 shares of the specialty pharma Get Jazz Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… Click here for the details JAZZ Media Mentions By Week JAZZ Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JAZZ News Sentiment▼0.680.79▲Average Medical News Sentiment JAZZ News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JAZZ Articles This Week▼107▲JAZZ Articles Average Week Get Jazz Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRTX News RARE News ARWR News ACAD News BHC News RPRX News PRGO News CORT News SUPN News PCRX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JAZZ) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is about to pass AppleWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
